Clinical Trials Logo

Low Grade Glioma clinical trials

View clinical trials related to Low Grade Glioma.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT01358058 Active, not recruiting - Low Grade Glioma Clinical Trials

Proton Radiation Therapy for Gliomas

Start date: May 2011
Phase: N/A
Study type: Interventional

In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal tissue from exposure. This may reduce side effects that patients would normally experience with conventional radiation therapy. In this research study the investigators are looking to determine if proton radiation with a reduced field size will be as effective in controlling tumor growth as photon therapy, while reducing the treatment-related side effects observed in patients with brain tumors.

NCT ID: NCT01288235 Active, not recruiting - Brain Tumor Clinical Trials

Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation

Start date: February 2011
Phase: Phase 2
Study type: Interventional

Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects. This research study is looking at a different form of radiation called proton radiotherapy which helps spare normal tissues while delivering radiation to the tumor or tumor bed. Proton techniques irradiate 2-3 times less normal tissue then standard radiation. This therapy has been used in treatment of other cancers and information from those other research studies suggests that this therapy may help better target brain tumors then standard radiation.

NCT ID: NCT01089101 Active, not recruiting - Low Grade Glioma Clinical Trials

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Start date: April 19, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.